2 growth shares that could help you beat the market

Royston Wild reveals two stocks with great profits potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Glanbia (LSE: GLB) moved modestly higher on the back of its latest trading details, the stock last up 1% from the mid-week close. But share picker appetite would no doubt have been stronger in the absence of the broader risk aversion currently sweeping world markets.

The food group continued to see revenues soar during January-June, it announced, the top line swelling 11.5% to €2.05bn. On a constant currency basis this was up 9.9% year-on-year.

As a result it saw EBITA soar 9.2% to €192.8m. The company advised that the sale of its 60% stake in Dairy Ireland and the division’s related assets last month had been classified as discontinued operations in the firm’s half-time numbers.

Chief executive Siobhán Talbot said: “Glanbia Nutritionals and Joint Ventures were the main drivers of growth in the first half and we believe second half earnings progression will also be driven by Glanbia Performance Nutrition where good organic growth is expected for the remainder of the year.”

Sales at Glanbia Nutritionals leapt 9% at stable exchange rates in the first half, while revenues at Joint Ventures and Associates increased 23.2% from the corresponding 2016 period.

And growing global demand for sports nutrition products also underpinned the strong first-half sales performance — the top line at Glanbia Performance Nutrition grew 5.4% in the period at constant currencies.

Talbot added that the Irish business remains on course to report pro-forma adjusted earnings per share growth of 7%-10% on a constant currency basis.

On the right path

The City certainly believes Glanbia is on course to keep earnings on an upward tilt, the company supported by an improvement in dairy markets and robust demand across the business. As such, bottom line rises of 6% are chalked in for both 2017 and 2018 respectively, although today’s sunny update may prompt an upgrade of these forecasts.

While dealing on a forward P/E ratio of 18.9 times, I reckon the Kilkenny company is worthy of a slight premium.

Rest easy

InterContinental Hotels Group (LSE: IHG) is another stock expected to deliver chunky bottom-line growth in the near-term and beyond.

In 2017, the global hotelier is predicted to deliver an 18% earnings improvement, and to follow this up with a 6% advance next year. And given the prospect of further rises in the coming years, I reckon InterContinental is also a terrific pick regardless of its slightly-heady forward P/E reading of 22 times.

The Buckinghamshire business saw revenues at constant exchange rates continue to chug higher in the first half, up 4% year-on-year to $788m, it announced last week. This underpinned a 7% rise in underlying operating profit which clocked in at $365m.

While the business saw REVpar (or revenues per available room) rise 2.1% in the period, this slowed to 1.5% in the second quarter from 2.7% in the prior three months, thanks in no small part to the impact of a later Easter on its US hotels — REVpar here fell 0.4% during April-June.

However, I believe the broad strength of the economy Stateside should push revenues here higher again sooner rather than later. And with InterContinental also continuing to make progress in Europe and China, I think the business remains a great share for those seeking excellent long-term growth.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »